EY制药公司的药品研发战略研究

发布时间：2019-03-12 12:32

【摘要】：目前我国的中小型制药企业占制药企业总数的绝大多数，药品研发也多以仿制药品种为主，缺乏系统有效的规划与战略，中小企业如何通过药品研发战略的制定与实施，实现品种的创新获取竞争优势，国内目前对此研究较少，本文通过对EY制药的研发状况的分析与研究，，提出了EY制药的药品研发战略与实施的保障措施。论文研究中理论与实践相结合，首先对国内制药行业现状与企业药品研发战略研究情况进行回顾，其次运用企业竞争力理论、战略管理理论、产品生命周期理论，分析了EY制药药品研发的内部优势和劣势及面临外部的竞争环境，按照利用内部优势资源和外部机会，回避内部劣势和外部威胁的思路，提出了EY制药的药品研发战略：在新产品选择上，重点先开发市场前景好的仿制药和对已有品种的二次开发，再开发相对容易成功的“me一too”药物，最终实现完全创新品种的研发；在药品研发模式上，可以根据不同情形选择联合研发与自主研发，需特别重视与CRO公司合作；三是在研发投入机制上，可以实行多渠道融资形式，获取研发资金。同时提出了EY制药药品研发的战略重点，为战略实施提供原则性指导，最后制定出详细的药品研发战略实施步骤，以及EY制药药品研发战略实施的配套保障措施。药品研发战略是制药企业发展战略的重要组成部分，论文尝试帮助EY制药制定药品研发战略，并制定措施保障战略实施，给企业在研发方向选择上给予明确指导，从而实现企业的发展战略规划，也为国内其他中小制药企业战略制定提供参考，为促进我国医药产业的做大做强尽一份努力。
[Abstract]:At present, the small and medium-sized pharmaceutical enterprises in China account for the vast majority of the total number of pharmaceutical enterprises, and the majority of drug research and development is mainly based on generic drugs. There is a lack of systematic and effective planning and strategy. How to formulate and implement the drug research and development strategy by SMEs? At present, there is little research on this issue in China. Through the analysis and research on the research and development status of EY pharmaceutical, this paper puts forward the R & D strategy of EY pharmaceutical and the guarantee measures for its implementation. Firstly, the current situation of domestic pharmaceutical industry and the research situation of drug research and development strategy are reviewed. Secondly, the theory of enterprise competitiveness, the theory of strategic management, the theory of product life cycle, and the theory of product life cycle are used. The internal strengths and weaknesses of EY pharmaceutical research and development and the external competitive environment are analyzed. According to the idea of using internal advantage resources and external opportunities to avoid internal weaknesses and external threats, The strategy of drug research and development for EY Pharmaceuticals is put forward: in the selection of new products, the emphasis should be placed on the development of generic drugs with good market prospects and the secondary development of existing products, and then the relatively successful "me-too" drugs, which are relatively easy to be successfully developed. Finally realize the research and development of completely innovative varieties; In the mode of drug research and development, joint R & D and independent R & D can be selected according to different situations, and special attention should be paid to cooperating with CRO Company. Thirdly, in R & D input mechanism, multi-channel financing can be carried out to obtain R & D funds. At the same time, the strategic emphasis of EY pharmaceutical drug research and development is put forward, which provides the principle guidance for the implementation of the strategy. Finally, the detailed implementation steps of the drug R & D strategy and the supporting safeguard measures for the implementation of the EY pharmaceutical drug R & D strategy are worked out. Drug research and development strategy is an important part of the development strategy of pharmaceutical enterprises. This paper attempts to help EY pharmaceutical to formulate drug research and development strategy, and to formulate measures to ensure the implementation of the strategy, so as to give clear guidance to enterprises in the choice of R & D direction. In order to realize the strategic planning of the development of enterprises, it also provides reference for other small and medium-sized pharmaceutical enterprises in China, and makes a great effort to promote the growth and strength of the pharmaceutical industry in China.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F426.72;F273.2

【参考文献】